Royal Bank Of Canada Raises AveXis, Inc. (AVXS) Price Target to $97.00
AveXis, Inc. (NASDAQ:AVXS) had its price target boosted by Royal Bank Of Canada from $92.00 to $97.00 in a report issued on Friday morning, MarketBeat.com reports. Royal Bank Of Canada currently has a sector perform rating on the stock.
AVXS has been the topic of a number of other research reports. Nomura started coverage on shares of AveXis in a research report on Monday, August 28th. They issued a reduce rating and a $52.00 price target on the stock. Zacks Investment Research lowered shares of AveXis from a buy rating to a hold rating in a research report on Monday, October 30th. Canaccord Genuity started coverage on shares of AveXis in a research report on Thursday, October 26th. They issued a hold rating and a $110.00 price target on the stock. Wells Fargo & Company reissued an outperform rating on shares of AveXis in a research report on Friday, September 29th. Finally, BMO Capital Markets reaffirmed an outperform rating and set a $130.00 target price (up previously from $123.00) on shares of AveXis in a research report on Thursday, October 12th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have given a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $108.26.
AveXis (NASDAQ:AVXS) traded down $3.52 during trading hours on Friday, hitting $95.79. 739,200 shares of the stock were exchanged, compared to its average volume of 435,865. AveXis has a 12 month low of $44.68 and a 12 month high of $108.27.
AveXis (NASDAQ:AVXS) last released its quarterly earnings results on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.48) by ($0.04). During the same quarter in the prior year, the company earned ($0.87) EPS. sell-side analysts forecast that AveXis will post -5.55 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Royal Bank Of Canada Raises AveXis, Inc. (AVXS) Price Target to $97.00” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://theolympiareport.com/2017/11/13/royal-bank-of-canada-raises-avexis-inc-avxs-price-target-to-97-00.html.
In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $93.25, for a total value of $165,985.00. Following the sale, the vice president now owns 1,780 shares of the company’s stock, valued at approximately $165,985. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Brian K. Kaspar sold 15,000 shares of the business’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $101.46, for a total transaction of $1,521,900.00. The disclosure for this sale can be found here. Insiders sold a total of 35,340 shares of company stock worth $3,559,683 in the last three months. Insiders own 18.60% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the business. Westfield Capital Management Co. LP bought a new stake in AveXis in the 3rd quarter valued at $39,563,000. Schwab Charles Investment Management Inc. increased its holdings in AveXis by 25.4% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 108,513 shares of the company’s stock valued at $10,497,000 after buying an additional 21,993 shares during the period. Wells Fargo & Company MN increased its holdings in AveXis by 59.6% in the 3rd quarter. Wells Fargo & Company MN now owns 26,170 shares of the company’s stock valued at $2,531,000 after buying an additional 9,769 shares during the period. Amalgamated Bank increased its holdings in AveXis by 19.6% in the 3rd quarter. Amalgamated Bank now owns 3,187 shares of the company’s stock valued at $308,000 after buying an additional 523 shares during the period. Finally, Legal & General Group Plc increased its holdings in AveXis by 76.4% in the 3rd quarter. Legal & General Group Plc now owns 10,283 shares of the company’s stock valued at $1,000,000 after buying an additional 4,455 shares during the period. 94.96% of the stock is currently owned by hedge funds and other institutional investors.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.